Interleukin Inhibitors Market Report 2026

The interleukin inhibitors market size has grown rapidly in recent years. It will grow from $57.87 billion in 2025 to $68.56 billion in 2026 at a compound annual growth rate (CAGR) of 18.5%. The growth in the historic period can be attributed to limited availability of interleukin inhibitors, growing prevalence of autoimmune diseases, increasing physician awareness and prescriptions, reliance on conventional therapies, expansion of hospital pharmacies and specialty clinics.

The interleukin inhibitors market size is expected to see rapid growth in the next few years. It will grow to $136.99 billion in 2030 at a compound annual growth rate (CAGR) of 18.9%. The growth in the forecast period can be attributed to development of next-generation biologics, rising investment in personalized immunotherapies, expansion of online pharmacies and telemedicine platforms, increasing regulatory approvals for novel interleukin inhibitors, growing government and healthcare initiatives for chronic disease management. Major trends in the forecast period include rising adoption of interleukin inhibitors for autoimmune disorders, growth in biologic therapies targeting il-17, il-23, il-1, il-5, and il-6, increasing focus on personalized and targeted immunotherapies, expansion of hospital and specialty clinic distribution channels, integration of telemedicine and digital platforms in chronic disease management.

The increasing prevalence of bacterial infections is expected to drive the growth of the interleukin inhibitors market in the coming years. Bacterial infections are illnesses caused by bacteria, which are microscopic, single-celled organisms capable of invading the body and triggering disease. Interleukin inhibitors play an important role in the treatment and management of bacterial infections by regulating immune responses and reducing inflammation associated with bacterial activity. For example, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, reported tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, representing a rise of 1,295 cases. Therefore, the growing burden of bacterial infections is contributing to the expansion of the interleukin inhibitors market.

Major companies operating in the interleukin inhibitors market are concentrating on the development of innovative therapies, such as monoclonal antibody biosimilars, to improve treatment effectiveness, lower healthcare costs, and expand patient access. A monoclonal antibody biosimilar is a biologic medicine that is highly similar to an approved reference antibody and demonstrates no clinically meaningful differences in safety or efficacy. For instance, in October 2025, Celltrion Inc., a South Korea-based biopharmaceutical company, launched AVTOZMA (tocilizumab-anoh) in an intravenous formulation in the United States. This therapy targets interleukin-6 receptors and is used in the management of conditions such as rheumatoid arthritis and other inflammatory disorders. The launch is intended to broaden access to advanced biologic treatments and improve clinical outcomes for patients.

In August 2023, Eli Lilly and Company, a US-based global pharmaceutical company, acquired DICE Therapeutics, Inc. for an undisclosed amount. Through this acquisition, Eli Lilly aims to strengthen its immunology portfolio, accelerate the development of novel therapies, and enhance its pipeline focused on autoimmune and inflammatory diseases. DICE Therapeutics, Inc. is a US-based biopharmaceutical company specializing in the development of interleukin inhibitor therapies.

Major companies operating in the interleukin inhibitors market are Sanofi S.A., GlaxoSmithKline plc, Novartis International AG, Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., AbbVie Inc., Sun Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Janssen Biotech Inc., Ortho Dermatologics, Amgen Inc., Celgene Corporation, Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Incyte Corporation, Kyowa Kirin Co Ltd., Astellas Pharma Inc., Ipsen Biopharmaceuticals Inc.

North America was the largest region in the interleukin inhibitors market in 2025. The regions covered in the interleukin inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interleukin inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the interleukin inhibitors market by raising the cost of imported biologics, active pharmaceutical ingredients, and delivery devices, which has slowed the supply of IL-17, IL-23, IL-1, IL-5, and IL-6 inhibitors. Hospital and retail pharmacies in North America and Europe, which rely heavily on imports, are most affected. The tariffs have led to increased treatment costs and supply chain delays, but they have also promoted domestic manufacturing, innovation in cost-effective therapies, and development of alternative distribution channels.

The interleukin inhibitors market research report is one of a series of new reports that provides interleukin inhibitors market statistics, including interleukin inhibitors industry global market size, regional shares, competitors with a interleukin inhibitors market share, detailed interleukin inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the interleukin inhibitors industry. This interleukin inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Interleukin inhibitors are substances used to suppress immune system activity by blocking the function of interleukins. Interleukins are a group of cytokines produced by white blood cells, including lymphocytes, monocytes, and macrophages, in response to infection and play a critical role in regulating immune responses.

The primary types of interleukin inhibitors include IL-17, IL-23, IL-1, IL-5, IL-6, and others. Interleukin-17 belongs to a pro-inflammatory cystine knot cytokine family and is produced by a subset of T helper cells, known as T helper 17 cells, in response to stimulation by IL-23. These inhibitors are used in applications such as psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, and others, and are distributed through channels including hospital pharmacies, retail pharmacies, and online pharmacies.

The interleukin inhibitors market consists of sales of anakinra, canakinumab, and rilonacept. Values in this market are ''factory gate values,'' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.